The plaque psoriasis market is witnessing rapid advancements propelled by innovative biologic therapies and increasing awareness of chronic skin diseases. As new treatment modalities gain ground, the industry size and market dynamics are evolving, reflecting heightened market growth and shifting market opportunities worldwide.
Market Size and Overview
The Global Plaque Psoriasis Market size is estimated to be valued at USD 32.28 billion in 2025 and is expected to reach USD 52.17 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2025 to 2032.
This Plaque Psoriasis Market growth is driven by increasing prevalence of autoimmune disorders, enhanced diagnosis capabilities, and expanding market revenue streams from novel drug launches. Continual product innovation, alongside rising healthcare infrastructure investments in emerging regions, is further expanding the market scope.
Key Takeaways
- Dominating Region: North America continues to dominate the plaque psoriasis market share in 2025, supported by high healthcare expenditure and early adoption of biologic therapies.
- Fastest Growing Region: Asia Pacific is the fastest-growing region, with increasing government initiatives in countries like India and China to improve psoriasis diagnosis and treatment access.
- Segment Categories:
- Treatment Type: Biologics remain the dominant segment due to their targeted mechanisms, while the small molecules segment is the fastest-growing sub-segment, driven by therapies such as newer oral Janus kinase (JAK) inhibitors. For instance, amivantamab’s increasing adoption in 2024 underscored growth potential in targeted synthetic therapeutics.
- Distribution Channel: Hospital pharmacies continue to hold the largest market share; however, online pharmacies exhibit rapid growth fueled by COVID-19-induced telemedicine expansion, as seen in 2025 market insights.
- End User: Dermatology clinics dominate due to specialized care requirements, while homecare settings demonstrate fast-paced growth, shaped by shifting patient preferences for self-managed treatment options.
Market Key Trends
A significant trend shaping the plaque psoriasis market relates to the surge in biologic drug approvals combined with enhanced patient-centric care. In 2024 and 2025, multiple biologic therapies targeting IL-23 and IL-17 pathways gained regulatory clearance, reflecting a shift toward precision medicine. For example, the launch of novel IL-23 inhibitors in mid-2024 significantly impacted market revenue, offering more durable and safer long-term treatment options than traditional systemic therapies. The increasing integration of digital health platforms also supports market dynamics by enabling better disease monitoring and adherence, thereby addressing market challenges related to treatment compliance. These changes are directly influencing market growth strategies, encouraging market players to invest in R&D and patient education initiatives to capitalize on expanding market opportunities.
Key Players
The plaque psoriasis market comprises prominent market players such as AbbVie Inc., Novartis International AG, Johnson & Johnson (Janssen Pharmaceuticals), Eli Lilly and Company, and Amgen Inc., among others. These market companies are actively adopting market growth strategies including collaborations, acquisitions, and geographic expansions to strengthen their market presence. During 2024-2025, strategic partnerships between major pharmaceutical firms and biotech companies accelerated innovation pipelines, resulting in faster product launches. Additionally, expansions into emerging markets have expanded sales channels and enhanced market share. For instance, AbbVie’s successful launch of new biologics in Asia Pacific contributed substantially to their global market revenue and reinforced their competitive positioning within the plaque psoriasis market.
FAQs
1. Who are the dominant players in the Plaque Psoriasis Market?
Key market players include industry leaders involved in biologics and novel therapies, notably AbbVie Inc., Novartis International AG, Johnson & Johnson (Janssen Pharmaceuticals), Eli Lilly and Company, and Amgen Inc.
2. What will be the size of the Plaque Psoriasis Market in the coming years?
The market is projected to grow from USD 32.28 billion in 2025 to USD 52.17 billion by 2032, reflecting a CAGR of 7.1% driven by innovation and increasing demand.
3. Which treatment category holds the largest growth opportunity in plaque psoriasis?
The biologics segment dominates market share, but small molecules, especially targeted synthetic therapies like JAK inhibitors, present the fastest-growing opportunity.
4. How will market development trends evolve over the next five years?
Market trends will focus on biologic advancements, patient-centric digital health integration, and expansion into emerging regions, influencing market growth strategies.
5. What is the nature of the competitive landscape and challenges in the Plaque Psoriasis Market?
The competitive landscape is dynamic with intense R&D activities and collaborations. Market challenges include high treatment costs and patient adherence issues, which are being mitigated through innovative delivery systems and patient support programs.
Get more insights on : Plaque Psoriasis Market
Get this Report in Japanese Language: 尋常性乾癬市場
Get this Report in Korean Language: 플라크건선시장
Author Bio:
Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )
Comments
0 comment